Pharmacologist & Investment Committee Member
Dr Qibing Mei is a world-leading pharmacologist who has dedicated his career to leadership in new drug evaluation. His expertise has been put to impressive effect with his leadership in establishing best practice drug evaluation in China.
Currently Dr Mei is Chief Scientist of the HK Biotech R&D team. He has engaged in pharmacology and new drug evaluation for 41 years and completed more than 100 pre-clinical evaluations of new drugs.
Early in his career, Dr Mei completed postdoctoral research at the University of Pennsylvania in 1991. He organised the establishment of China’s first drug-ability evaluation centre, and the certification of the first drug toxicology laboratory in Shanghai, China that complies with the OECD Principles of Good Laboratory Practice (GLP).
Additionally, he has undertaken 11 national-level projects, including the National 973 Plan, the State Project for Essential Drug Research and Development, the National 863 Project and the National Natural Science Foundation Project, and authored more than 500 publications, 130 of which are SCI papers, and 13 teaching materials and monographs.
Dr Mei has recently become an independent director of the Luzhou New Drug Evaluation and Research Centre.